Canadian Respiratory Journal

Research Article

Blood Eosinophil Count as a Predictive Biomarker of Chronic Obstructive Pulmonary Disease Exacerbation in a Real-World Setting

Table 4

Univariate and multivariate analyses of inhalation therapy and exacerbation in all patients.


	Univariate		Multivariate
	Odds ratio (95% CI)	value	Odds ratio (95% CI)	value

Component included
ICS	2.60 (1.07–6.31)	0.035	1.68 (0.66–4.22)	0.271
LAMA	0.68 (0.28–1.70)	0.415	0.56 (0.21–1.49)	0.253
LABA	N.D	N.D	N.D	N.D

Inhalation therapy
ICS mono	N.D	N.D	—	—
LAMA mono	N.D	N.D	—	—
LABA mono	2.29 (0.71–7.38)	0.164	—	—
ICS + LABA	1.69 (0.53–5.33)	0.374	2.41 (0.54–10.73)	0.247
LAMA + LABA	0.53 (0.19–1.48)	0.225	0.87 (0.21–3.47)	0.847
ICS + LABA + LAMA	2.33 (0.95–5.73)	0.065	2.04 (0.57–7.30)	0.269

ICS, LAMA, LABA, and ICS + LABA, LAMA + LABA, and ICS + LABA + LAMA were included in each multivariate analysis. The analysis was adjusted for COPD severity. Statistical significance is marked using the bold font. ICS, inhaled corticosteroid; LAMA, long-acting muscarinic antagonist; and LABA, long-acting β²-agonist.